Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 May 2022 | Story Anthony Mthembu | Photo Supplied
Alina Ntsiapane
Alina Ntsiapane obtained second place in the partners division of the ILRI CapDev Grand Challenge research pitching contest.

Alina Ntsiapane, a PhD student at the University of the Free State, obtained second place in the partners category of the International Livestock Research Institute’s (ILRI) CapDev Grand Challenge research pitching contest, which took place on 13 April 2022. The pitching contest is the first part of the CapDev Grand Challenge, which is a 10-month process aimed at equipping scientists with the necessary skills to contribute to new research. 

Presenting Research to a Tough Panel of Judges 

Ntsiapane was one of 30 contestants who presented their research virtually to a panel of esteemed judges. “It was not easy, it was very challenging for me because it was my first time presenting my PhD study and I had to do it live on an international platform,” expressed Ntsiapane. Although each contestant is thoroughly prepared for their respective presentations, Ntsiapane argues that some of the questions asked by the judges can be quite daunting. “Some of their questions were very challenging and I did not know how to respond to them, but they made me aware of ways in which I needed to improve my research,” she stated. However, regardless of the intensity of the pitching contest, Ntsiapane’s research allowed her to progress to the next stage of the CapDev Grand Challenge. She will be part of the rigorous 10-month training process that will begin in June 2022.

Ntsiapane’s Research Project

Ntsiapane’s PhD research focuses on the production of smallholder wool as a means to improve livelihoods in both Thaba ’Nchu and Botshabelo in the Free State. In fact, in the research Ntsiapane highlights that there has been a significant decline in the production of wool within the last three decades. As such, Ntsiapane believes it is imperative to create spaces that allow for the training of small-scale farmers, so that the production of wool can still be a possibility.
Consequently, Ntsiapane hopes that the 10-month training she will receive from the CapDev Grand Challenge will not only allow her to grow but will assist in opening doors for her. “I’m hoping to get exposure and to make connections with policy makers and the donors as well. This will assist me in achieving my goals,” she explained. 

Future Endeavours After the Training Course

Subsequent to the training course, Ntsiapane would like to utilise that knowledge by continuing to make her most recent project a reality. Ntsiapane is currently working on developing a television show aimed at providing adequate training to small-scale farmers, so that they are equipped with the necessary knowledge and understanding of the industry in which they find themselves. As such, being part of the CapDev Grand Challenge will allow her to learn some of the necessary ways in which this dream could become a reality. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept